Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems

Abbott (ABT) announced that Lingo and Libre Rio, two of its glucose monitoring system, have received FDA clearance. Lingo and Libre Rio are based on Abbott’s own Freestyle Libre continuous glucose monitoring (CGM) technology.The latest development is expected to expand the company’s Diabetes Care business.More in the NewsBoth the consumer biowearable devices are designed to cater to different needs. Lingo is for consumers who are 18 years or older and want a better understanding about their metabolic health ...